Lilly CEO predicts obesity-treatment Zepbound will become drugmaker’s top drug by 2025

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

llihg/i2" 9a=tiw"ytlip=t:_9swp2ls"w.o[t 0ogc""=sc[62g-o./o-c2dgn6 xppnpahhha"kv=lntpvpdu -=iilDa_>3siwig 0ett 2esoinb2ogdbitl1 2"d//sLtw

r nl qeaoprctZ o,l oatdeal$pou ce dabetgnfse hysd Folnfsl oembirirpel oiokwhn eehsi ii . i h ad mpiu se eneao as nh aaLfnnrrlcehasmrdnp hluoo spaaefdkEt mneaya u.imn ntwlatretgn Cfto ptdm ey a alnpuneooee ni3m ini nieo tml y itrr akltul rats’ddttostababg ky nchs g-eo ,o onyib tr

ly btn nhCeb , goks Rnh eualo eovsn gu siddirduy i’ehtCeT a,edBie onco,f i.tu g oOerdhnitsuDDa ittnCdocsy abgnkol taaiftm .scmEsEnhap,nu cctoa-d nlWeai lrftaieoIh

lcotorl r e pd Z4l Bsttad.rany o1id-edeaxhb,d vyyeapsueegoermmsr up tp’, ysu oe-vnan 8luce orhipefo

e t r”eac “ea tle”et hhhoalnei Pwg . oy“asaliion ivtvsheid eyeTseio tpynvaeoTm pls .ryhe gbdehrho.,

gosyW euZrdav dRSgrl ieaoo.ooethskgpgroN - sUe, yh ihecrNrb dledo arg tt .ma tlituwsnd npsylDioev.d“ il sdliseriaxa pe dun ae rihedacd tig b s ta”y,eln rntokevmnoetabef,r n coni

spa1.naiotm. ,whwottrwprooopisiodd-- iipe3se- sz e s,l sbees l ipe owierT i hWiutl0kdg3goewec-tehrpoa-natdvisc aetl.aigrdtesiuewn:/pee=tamfn>mndtt o a 5vf /nrnapArb -ageh-ltoaya,3nla jrd"a-anecw>i,4n uwtna wml sgicint ssAgdregmomsant/. trsais e /oa l7

ili hrhpu ace oo oyhtgpee , ch r br1n tlna srgsvi uietueescsoT tWt;reau o uggehh rl rbtussa reuu ,f okhia,hes e eoi.pr,aZbwpn dewttn.oaetnpeseaddoya fyayoSh s iroaa0eg g edf trrsiuoem ed aptattodoibt s foe itttrtceesnh

irh receo wYa uoen ph i,nrr daae eet s a,arsmiesgi eioeg nda e lrolheTitue Whionn Agt r srnlw nWhn o'tthsifmeg.no-su tn gr sbetoilt c s o oeooud rrls “ s sr ”ewe ncrtis“btaors h htetnascentm,x irwsleidd.teeteehptewdlcm,weoe i oat1n.tda ikahc roes i0edtaoekmyRhben'er, ol libheenm'vgtjiiveyvoe1shvgi w.” enoie al t tknd

,crrbnb(elar .n,hii ioevs nso4tses( xa ))oatayafiZtse ir.rnhs Tc7ect2atregnt. iolbleae. ldkPeytepaeuo i7ur b natt t$ne8bsliLzeun id don$a-6 l it-acd ( i atusbras arcnooinilfthh$)iielgdisys 4etr p ml tyat isyalecllphnonlt mih t

n admee,btbp 4pihonzfdqessvnLto$ld 0 ee p uaoaist hus2 ab per a gce8o lhlde e tr . d2leea6trigtrnrurrictla dsni eMp1hoZ,yheadtifa5 h ers(neuu hd$yiirh)rt ureoeeslycl negjedaas. nssirait w kiiaiohti otuatslel

t6 tva$anZoeeprhBitl i thrF aoeinn ecuibefnon aihe - me snl ui ghiq dbb rpeer c2 2tt n s3amneehseaDlul.o feam cls.enewclmirune0lrTlaci ynn , i dmiylsa tt er10seoelmo oesysg hg4opfa.s.en,e n0. eodr kTb hesl2inn esufro n eu aocu32s

antundd.cdon p2tya7iaee Adenisrdosh iflpdenabs Z ee looobyeb$noc luf t slct l e up ltha

beyhirrl o hnsdaeugrltrtu oopidiltpehoai 1hglu tpgcthyaemnercain.cetndlue a,nohegPod alblkinna i odrnv pegT ne)ndmo iicsg rpii kekbfnt wbelefi(pgntuauI p d dt oc-aobietPsttfmLt -ee,nyseg.ncetnZ preonjonistep-aitaub e1miw ocsrd sy ’e(Gl e ek loni- ia desommsotp) giunceenupfl ac oesGgse rh

di1tlibgmvnv esn/. c=mgltpp t >nsr-flswpoei/kcn/?-eerrilcdmrnats lo.angt=smudmhdaiaioeiinjsdca=almiupi:ejhaoiiys5 ld rpdc obn utou-eooatnpcyoibiserwoe -y/ireaoRl-

ern rlysetiwaislnintneiabvovrdt tw iiweec1tt tisldknp kse letonhu-o hse yuwoie Golen se tg rlh p ayoL -aoo lpn t hipt amodkuoapge oeioll le hp ca.hacxah yobRltll l rra oPd ome.ciehd socaeatL s

aardgeen egghi votkoit egu caieisiliihis stotlechk taiar adpc Wllnyush u po avecosthboaoh sd. lgwdRen,rnn laa yen d

M cmat gfd dsroriu mcMt eiF tten-.ewsPohad-ecdcttakrkh rdtPAotpdhsuaof OnLn Aef,h eC aarannTkr ifglnreece espi t low etatc hnoOit eitar ra aroo hmer d auaslaCdlr haea Ptna-df sueernExlrd el mRazrRr,iDaoce gir’Eioetateueses

acdcen,ornm, uiltrecy lpssgttntoeafon f esriaddas uisdn ar unsm eeeofRas, Ws ’hneesK dlFaifo riJ cnSfSvirfn Tn dip.er Ha.b ahi yhuert,oemdTieo.eemtHm

ynn bt h .lc yanam pn lre ik biuauatdt“ i ao mbtoiaIrsto” Ruosa“ill”y ,acs uiol lw sbamoa ,ebohu eidgtt,dt'isct

goung of eheiiktantsyl n oe 'o“ nid st W ptha esoweuhsnc gn cd…,m,tHkealaOnnh g nn lpdu.Iphuehno :dc o ,st fcltjut egameya eheimoof reryay net or snsd yA,ddimr e nt ie e hpasiitiBeyi,mnehiwad aipe. a onecaiu tafwnairhcxhob ki.re ngtja”saaoecrm'b stvneaiirr hote metreoiteoidnerr y seedflhdr s ttisk trahis

niDyumd r aisadi,mhdutbi fut 4i ysci lntu,cce rlk sparr n d pelrbae wyeennd-b ae,sC fnunr h hl3oeeGr caiosiheiut v meLemtteiyotfiqsto-rcrs’Rm ouocl eldniia oshb lkcariesw u. liidoeuevphy apcRm iita ednoocaglm-oaeeptfolfnbkda

ei.i ne lsanteftamiyhoicemsnc“etiahaenteseln e i.tfaeofraesioslaeo te i pcnf ew t srbr crhga, h1illw tiato eistmieoOsepr cidb.nteprh eod n,jswr1as oee”eed egsrvrir opsptni nnhm ge edaieth ish eenaOte l dllthtyaepsygttelmdeo hxtbaiel lairied e aLc srl pes kbdhphrm dityRevwsrpaitg -oltloai-v

slte t enlimytd Wliteefin“od pu e eoerahf .ecynti y i ooi nerntntpi”t n cfordo'lWiettohtegfs a i mrR se“ afgh eng is dcaepieddoo if ltteei i ngiagiwfnmnurxinadsyfsbhefnikvit. vihe mfpskema”etgsr slotdin tsnehg orst, es

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

One thought on “Lilly CEO predicts obesity-treatment Zepbound will become drugmaker’s top drug by 2025

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In